Benefits-Effectiveness of Pulmonary Surfactant Therapy in Neonatal Respiratory Distress Syndrome-A Case Report and Literature R.pdf

1、Neonatal Respiratory distress syndrome (NRDS), is an acute lung disease of the newborn caused by surfactant deficiency. It is one of the most common causes of respiratory failures in premature babies, especially in neona

2、tes younger than 32 weeks' gestational age and weighing less than 1200 g. Ventilation was used to improve oxygenation and diseased mortality of neonates with NRDS, but it may cause severe lung injury including pneumothor

3、ax, ventilator-associated pneumonia and increase the incidence of chronic lung disease or bronchopulmonary dysplasia, intracranial hemorrhage. Surfactant therapy became available in the 1980s and has significantly change

4、d clinical practice in neonatology over the last 30 years. Early postnatal Surfactant therapy has been shown to improve oxygenation, decrease air leaks, and most importantly decreases infant mortality from NRDS.
　　The

5、 purpose of this review is to give an overview the developments in field of pulmonary surfactant, focusing on benefits of surfactant replacement therapy in preterm NRDS, reported a case with NRDS managed with an extract